SRR2932830
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.430
- IL6_JAK_STAT3_SIGNALING+0.410
- ALLOGRAFT_REJECTION+0.370
- INTERFERON_GAMMA_RESPONSE+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- COAGULATION+0.290
- APICAL_SURFACE+0.280
- INFLAMMATORY_RESPONSE+0.280
- COMPLEMENT+0.250
- KRAS_SIGNALING_UP+0.250
Top 10 suppressed
- MYC_TARGETS_V2-0.560
- MYC_TARGETS_V1-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- OXIDATIVE_PHOSPHORYLATION-0.330
- MTORC1_SIGNALING-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.310
- PROTEIN_SECRETION-0.290
- CHOLESTEROL_HOMEOSTASIS-0.280
- G2M_CHECKPOINT-0.250
- GLYCOLYSIS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.885 |
| 2 | 09f3976d-4e95-41b4-bc0b-27eea3e20bb3 | — | — | 0.885 |
| 3 | TCGA-98-A53H-01A-12R-A262-07 | — | cohortA1 | 0.884 |
| 4 | TCGA-49-AARO-01A-12R-A41B-07 | — | cohortA1 | 0.879 |
| 5 | TCGA-55-7574-01A-11R-2039-07 | — | cohortMD2 | 0.874 |
| 6 | 59f108c6-677f-4cf2-89fd-6bd15133dd6f | — | — | 0.873 |
| 7 | SRR26320092 | — | — | 0.872 |
| 8 | TCGA-55-8621-01A-11R-2403-07 | — | cohortA1 | 0.872 |
| 9 | SRR1516085 | — | — | 0.871 |
| 10 | TCGA-99-AA5R-01A-11R-A39D-07 | — | cohortA1 | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |